Skip to main content

Advertisement

Table 2 Change in owners’ clinical score between presentation and 12 weeks

From: Evaluation of a spot-on imidacloprid-moxidectin formulation (Advocate®) for the treatment of naturally occurring esophageal spirocercosis in dogs: a double-blinded, placebo-controlled study

  Attitudea Activityb Regurgitationc Salivationd Appetitee
Week 1 Week 12 Week 1 Week 12 Week 1 Week 12 Week 1 Week 12 Week 1 Week 12
Doramectin 5 (3–5) 5 (3–5) 4 (2–5) 5 (2–5) 1.5 (1–4) 1 (1–2) 1 (1–5) 1 (1–5) 5 (1–5) 5 (2–5)
Advocate 3 (1–5) 5 (2–5) 2.5 (1–5) 5 (2–5) 2.5 (1–5) 1 (1–3) 1 (1–5) 1 (1–5) 5 (2–5) 5 (4–5)
  1. a1, very depressed, 5 excellent
  2. b1, normal; 5, severely decreased
  3. c1, none; 5, severe
  4. d1, none; 5, severe
  5. e1, anorectic; 5, excellent